Please assess the completion status of the following clinical trial:

Trial Title: Vardenafil ODT Versus Placebo in Males With Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males 18 years-of-age or older~* Stable, heterosexual relationship for at least 6 months~* A history of erectile dysfunction (ED) for at least 6 months~Exclusion Criteria:~* Any underlying cardiovascular condition, including unstable angina pectoris~* History of myocardial infarction, stroke or life-threatening arrhythmia within 6 months prior to visit 1~* Uncontrolled atrial fibrillation / flutter at screening~* History of surgical prostatectomy for prostate cancer~* Hereditary degenerative retinal disorders~* History of loss of vision because of Non-arteritic anterior ischemic optic neuropathy (NAION), temporary or permanent loss of vision~* Presence of penile anatomical abnormalities~* Subjects who have been confirmed with phenylketonuria (PKU)~* Spinal cord injury~* Resting or postural hypotension or hypertension~* Subjects who are taking nitrates or nitric oxide donors, androgens, anti-androgens, alpha- blockers, medication known to prolong QT interval, Human immunodeficiency virus (HIV) protease inhibitors, itraconazole or ketoconazole, an clarithromycin and erythromycin~* Use of any treatment for ED within 7 days of Visit 1~* History of congenital QT prolongation~* History of syncope within the last 6 months prior to entry into the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vardenafil ODT (STAXYN, BAY38-9456) (Type: EXPERIMENTAL): Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).